We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Xencor Inc (XNCR) USD0.01

Sell:$19.11 Buy:$19.15 Change: $0.11 (0.55%)
NASDAQ:1.16%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$19.11
Buy:$19.15
Change: $0.11 (0.55%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$19.11
Buy:$19.15
Change: $0.11 (0.55%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Contact details

Address:
465 N. HALSTEAD ST., SUITE 200
PASADENA
91107
United States
Telephone:
+1 (626) 3055900
Website:
https://xencor.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
XNCR
ISIN:
US98401F1057
Market cap:
$1.12 billion
Shares in issue:
61.12 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Bassil Dahiyat
    President, Chief Executive Officer, Founder and Director
  • Bart Cornelissen
    Chief Financial Officer, Senior Vice President
  • John Desjarlais
    Executive Vice President - Research, Chief Scientific Officer
  • Nancy Valente
    Executive Vice President, Chief Development Officer
  • Celia Eckert
    Senior Vice President, General Counsel, Company Secretary
  • Dane Leone
    Senior Vice President, Corporate Strategy

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.